A233250 Stock Overview
Median Diagnostics Inc. develops and sells immune diagnostic reagents based on genetic recombination and monoclonal antibody technologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Median Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,400.00 |
| 52 Week High | ₩25,950.00 |
| 52 Week Low | ₩10,500.00 |
| Beta | 0 |
| 1 Month Change | -0.80% |
| 3 Month Change | -14.78% |
| 1 Year Change | -45.85% |
| 3 Year Change | -69.00% |
| 5 Year Change | -60.88% |
| Change since IPO | -1.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| A233250 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.6% | 4.1% | 0.5% |
| 1Y | -45.9% | 6.6% | 4.7% |
Return vs Industry: A233250 underperformed the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A233250 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A233250 volatility | |
|---|---|
| A233250 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A233250's share price has been volatile over the past 3 months.
Volatility Over Time: A233250's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Oh Jin-sik | www.mediandiagnostics.com |
Median Diagnostics Inc. develops and sells immune diagnostic reagents based on genetic recombination and monoclonal antibody technologies. Its products include ELISA for swine, ruminants, and poultry; VDRG and VDRF rapid test kits; PCR and chip kits; standard reagents; biologicals, including antibodies for veterinary diagnostics, and antibodies and antigens for human diagnostics; and Covid-19 rapid test kits. The company was formerly known as Jeno Biotech Inc. and changed its name to Median Diagnostics Inc. in July 2017.
Median Diagnostics Inc. Fundamentals Summary
| A233250 fundamental statistics | |
|---|---|
| Market cap | ₩21.73b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A233250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A233250 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A233250 perform over the long term?
See historical performance and comparison